Thoen J, Helgetveit K, Førre O, Haile Y, Kåss E
Institute of Immunology and Rheumatology, Rikshospitalet, Oslo, Norway.
Scand J Rheumatol. 1988;17(2):91-102. doi: 10.3109/03009748809098768.
The effects of piroxicam and D-penicillamine on T lymphocytes, NK cell activity and rheumatoid factor production as well as clinical parameters were studied in patients with rheumatoid arthritis. The level of total rheumatoid factor fell during treatment with D-penicillamine (p less than 0.02) and there was a positive correlation (K greater than 0.50, p less than 0.05) between this fall in rheumatoid factor and the improvement of several clinical activity parameters. No significant change was observed in the level of rheumatoid factor during treatment with piroxicam. Natural killer cell activity decreased from 21.1 +/- 2.5 to 15.8 +/- 1.9 after treatment with piroxicam for 3 weeks (p less than 0.05) as compared with changes in the controls. No change in natural killer cell activity was seen after treatment with D-penicillamine. Moreover, no significant changes in the numbers of T4+ and T8+ lymphocytes nor in the numbers of HLA-DR positive T cells were seen in the two treatment groups. Both laboratory and clinical activity parameters improved during the treatment with D-penicillamine, while only subjective parameters improved during treatment with piroxicam.
研究了吡罗昔康和青霉胺对类风湿性关节炎患者T淋巴细胞、自然杀伤细胞活性、类风湿因子产生以及临床参数的影响。在使用青霉胺治疗期间，类风湿因子总量水平下降（p<0.02），且类风湿因子的这种下降与几个临床活动参数的改善之间存在正相关（K>0.50，p<0.05）。在使用吡罗昔康治疗期间，类风湿因子水平未观察到显著变化。与对照组相比，使用吡罗昔康治疗3周后，自然杀伤细胞活性从21.1±2.5降至15.8±1.9（p<0.05）。使用青霉胺治疗后，自然杀伤细胞活性未见变化。此外，两个治疗组中T4+和T8+淋巴细胞数量以及HLA-DR阳性T细胞数量均未见显著变化。在使用青霉胺治疗期间，实验室和临床活动参数均有所改善，而在使用吡罗昔康治疗期间，仅主观参数有所改善。
